• Single screening for Lynch syndrome beats sequential tests in CRC

    on March 30th, 2018
    FROM JAMA ONCOLOGY Physicians could more accurately test patients with colon cancer for Lynch syndrome by using a single tumor sequencing test instead of the current protocol of up to six sequential tests, a new study suggests. The process may also be faster in some cases. “We found that up-front [...]
  • Think about breast cancer surveillance for transgender patients

    on March 30th, 2018
    REPORTING FROM ENDO 2018 CHICAGO (FRONTLINE MEDICAL NEWS) – Both transgender men and transgender women had an increased risk of breast cancer compared with a male, but not a female, reference population, said Christel de Blok, MD, sharing results of a Dutch national study. The study included 3,078[...]
  • Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC

    on March 30th, 2018
    REPORTING FROM THE NCCN ANNUAL CONFERENCE ORLANDO (FRONTLINE MEDICAL NEWS) – Checkpoint blockade is associated with reduced toxicity when compared with antiangiogenic therapies for the treatment of advanced non–small-cell lung cancer, a systematic review and meta-analysis suggests. In 16,810 pat[...]
  • FDA expands indication for blinatumomab in treating ALL

    on March 29th, 2018
    The Food and Drug Administration has granted accelerated approval to blinatumomab for treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). This is the first FDA-approved treatment for those with [...]
  • Oncologist-led BRCA mutation testing and counseling may reduce wait times for women with ovarian cancer

    on March 28th, 2018
    FROM THE JOURNAL OF CLINICAL ONCOLOGY For women with ovarian cancer, an oncologist-led BRCA1/2 (BRCAm) counseling process is associated with favorable waiting times for test results and high levels of satisfaction, according to results of a prospective observational study. The median turnaround time[...]
  • Ibrutinib plus venetoclax is active in mantle cell lymphoma

    on March 27th, 2018
    FROM THE NEW ENGLAND JOURNAL OF MEDICINE In mantle cell lymphoma (MCL), ibrutinib plus venetoclax significantly improved the complete response rate, compared with what has been previously reported for ibrutinib alone, according to results of a phase 2 study. Clinical outcomes with the combination se[...]
  • Survival worse with alcohol-related HCC, compared with other types

    on March 27th, 2018
    FROM CANCER Hepatocellular carcinoma (HCC) related to alcohol use tends to be diagnosed at a later stage than HCC from other causes, which contributes to reduced overall survival among patients with alcoholic HCC, investigators in a prospective French study said. Among 894 patients diagnosed with HC[...]
  • HDAC inhibition may boost immune therapy efficacy in breast cancer

    on March 27th, 2018
    REPORTING FROM THE NCCN ANNUAL CONFERENCE ORLANDO (FRONTLINE MEDICAL NEWS) – The novel combination of entinostat and nivolumab with or without ipilimumab showed encouraging safety, tolerability, and antitumor activity in early results from an ongoing phase 1 trial of patients with advanced breast [...]
  • Over one-third report financial burden from breast cancer treatment

    on March 27th, 2018
    REPORTING FROM SSO 2018 CHICAGO (FRONTLINE MEDICAL NEWS) – Women who have treatment for breast cancer seldom talk about the costs of care with their medical team, but a study out of Duke University has found that more than one-third reported having a financial burden from their breast cancer treat[...]
  • CBC data can predict immunotherapy responses in NSCLC

    on March 25th, 2018
    REPORTING FROM THE NCCN ANNUAL CONFERENCE ORLANDO (FRONTLINE MEDICAL NEWS) – Information readily available on complete blood count can help predict response to immunotherapy and outcomes in patients with advanced non–small cell lung cancer, according to findings from a review of 157 cases. Speci[...]
  • Lower socioeconomic status linked with poor NSCLC prognosis in those with pretreatment weight loss

    on March 23rd, 2018
    FROM JOURNAL OF ONCOLOGY PRACTICE Socioeconomic status, as measured by insurance status, was associated with survival among patients with non–small cell lung cancer (NSCLC) and pretreatment cancer-associated weight loss, in a retrospective review of medical records. Investigators identified 1,366 [...]
  • FDA approves nilotinib for children with CML

    on March 23rd, 2018
    Nilotinib is now approved for use by children aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. The Food and Drug Administration expanded the drug’s indication to include use as first- and second-line treatment in children. The a[...]
  • Chemotherapy, metabolic pathway may affect CAR T-cell potential

    on March 22nd, 2018
    FROM AACR 2018 Two critical factors – prior exposure to chemotherapy and a glycolytic metabolism – appear to degrade the potential of T cells to become chimeric antigen receptor–T cells. Chemotherapy, especially with cyclophosphamide and doxorubicin, seems particularly toxic to T cells, damagi[...]
Back to top